These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 29899103)
1. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models. Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103 [TBL] [Abstract][Full Text] [Related]
2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533 [TBL] [Abstract][Full Text] [Related]
3. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Chong H; Zhu Y; Yu D; He Y J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526 [TBL] [Abstract][Full Text] [Related]
5. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304 [TBL] [Abstract][Full Text] [Related]
6. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118 [TBL] [Abstract][Full Text] [Related]
7. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101 [TBL] [Abstract][Full Text] [Related]
8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437 [TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition. Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478 [TBL] [Abstract][Full Text] [Related]
10. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245 [TBL] [Abstract][Full Text] [Related]
11. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Xue J; Chong H; Zhu Y; Zhang J; Tong L; Lu J; Chen T; Cong Z; Wei Q; He Y Cell; 2022 Jan; 185(1):131-144.e18. PubMed ID: 34919814 [TBL] [Abstract][Full Text] [Related]
12. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566 [TBL] [Abstract][Full Text] [Related]
13. Development of potent and long-acting HIV-1 fusion inhibitors. Chong H; Wu X; Su Y; He Y AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736 [TBL] [Abstract][Full Text] [Related]
14. Protocol for evaluating CD8 Sun Y; Zhang J; Tong L; Lu J; Chen T; Wei Q; He Y; Cong Z; Xue J STAR Protoc; 2022 Sep; 3(3):101479. PubMed ID: 35776642 [TBL] [Abstract][Full Text] [Related]
15. Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19. He L; Wang C; Zhang Y; Chong H; Hu X; Li D; Xing H; He Y; Shao Y; Hong K; Ma L Front Immunol; 2023; 14():1199938. PubMed ID: 37256122 [TBL] [Abstract][Full Text] [Related]
16. SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques. Mandell CP; Reyes RA; Cho K; Sawai ET; Fang AL; Schmidt KA; Luciw PA Virology; 1999 Dec; 265(2):235-51. PubMed ID: 10600596 [TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466 [TBL] [Abstract][Full Text] [Related]
18. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Humbert M; Rasmussen RA; Song R; Ong H; Sharma P; Chenine AL; Kramer VG; Siddappa NB; Xu W; Else JG; Novembre FJ; Strobert E; O'Neil SP; Ruprecht RM Retrovirology; 2008 Oct; 5():94. PubMed ID: 18928523 [TBL] [Abstract][Full Text] [Related]
19. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses. Reimann KA; Watson A; Dailey PJ; Lin W; Lord CI; Steenbeke TD; Parker RA; Axthelm MK; Karlsson GB Virology; 1999 Mar; 256(1):15-21. PubMed ID: 10087222 [TBL] [Abstract][Full Text] [Related]
20. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys. Müller S; Margolin DH; Min G Hybridoma; 1997 Feb; 16(1):17-21. PubMed ID: 9085123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]